Loviride

This article does not cite any sources. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (March 2015) (Learn how and when to remove this template message)

Loviride

Clinical data
Other names	R089439
ATC code	None
Identifiers
show IUPAC name 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide
CAS Number	147362-57-0 N
PubChem CID	3963
ChemSpider	3826 Y
UNII	3S1R1LZ09H
KEGG	D04786 Y
ChEMBL	ChEMBL37624 Y
Chemical and physical data
Formula	C17H16Cl2N2O2
Molar mass	351.23 g·mol−1
3D model (JSmol)	Interactive image
show SMILES Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N
show InChI InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23) Y Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N Y
NY (what is this?)

Loviride (also called loveride^{[citation needed]}) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance the NNRTIs efavirenz and nevirapine.

Synthesis[]

Loviride synthesis: Janssen Pharmaceutica U.S. Patent 5,407,961 (1995).

External links[]

• aidsmap

This antiinfective drug article is a stub. You can help Wikipedia by .

• v
• t